This isn't exactly a secret.
23&me talk about it on their blog.
They seem pretty proud of it.
One of the options when you send your sample to them is a box for whether you consent to your data being used in research.
We have also built a significant research team that has published over 100 scientific papers. In 2015, we launched 23andMe Therapeutics to develop novel treatments and cures based on genetic insights from the consented 23andMe community.
Today, I am thrilled to announce that we are launching a collaboration with GlaxoSmithKline (GSK) to accelerate our ability to make those novel treatments and cures a reality.
I hear regularly from customers that they want to be part of a solution that is improving health care. We all have some disease or health issue that we care about. 23andMe has created a research platform to enable customers to actively participate in research — to not wait for solutions to appear, but for people to come together and make discoveries happen. By working with GSK, we believe we will accelerate the development of breakthroughs. Our genetic research — powered by millions of customers who have agreed to contribute — combined with GSK’s expertise in drug discovery and development, gives us the best chance for success.
We are excited to join The Michael J. Fox Foundation for Parkinson's Research (MJFF) as a partner on Fox Insight, an online study designed to collect data from Parkinson's patients to inform research and drug development. MJFF is the largest non-profit funder of Parkinson's research and shares our goal of revolutionizing Parkinson's research through genetics.
When you join Fox Insight, you may be eligible to participate in the Fox Insight Genetic Sub-study powered by 23andMe. You could make a difference.